• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by DiaMedica Therapeutics Inc.

    5/27/22 4:44:54 PM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DMAC alert in real time by email
    SC 13G 1 d275967dsc13g.htm SC 13G SC 13G

     

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. *)

     

     

    DiaMedica Therapeutics Inc.

    (Name of Issuer)

    Voting Common Shares, no par value per share

    (Title of Class of Securities)

    25253X207

    (CUSIP Number)

    April 20, 2022

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐

    Rule 13d-1(b)

     

    ☒

    Rule 13d-1(c)

     

    ☐

    Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No 25253X207    Page 2 of 5

     

      (1)   

    Names of reporting persons

     

    Richard Jacinto II

      (2)  

    Check the appropriate box if a member of a group (see instructions)

    (a)  ☐        (b)  ☐

     

      (3)  

    SEC use only

     

      (4)  

    Citizenship or place of organization

     

    United States

    Number of

    shares

    beneficially

    owned by

    each

    reporting

    person

    with:

       (5)    

    Sole Voting Power

     

    1,649,053 voting common shares (1)

       (6)   

    Shared Voting Power

     

    0

       (7)   

    Sole Dispositive Power

     

    1,649,053 voting common shares (1)

       (8)   

    Shared Dispositive Power

     

    0

      (9)  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,649,053 voting common shares (1)

    (10)  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

    ☐

    (11)  

    Percent of Class Represented by Amount in Row (9)

     

    6.2% (2)

    (12)  

    Type of Reporting Person (See Instructions)

     

    IN

     

    (1)

    Consists of (i) 100,000 voting common shares held by Fidelity Roth IRA Richard Jacinto II – Roth IRA – FMTC Custodian, of which Richard Jacinto II is the beneficiary, and (ii) 1,549,053 voting common shares held by NFS/FMTC Roth IRA FBO Richard Jacinto II, of which Richard Jacinto II is the beneficiary.

     

    (2)

    Based on 26,443,067 voting common shares of the Issuer outstanding as of May 3, 2022.


    CUSIP No 25253X207    Page 3 of 5

     

    Item 1(a).

    Name of Issuer:

    DiaMedica Therapeutics Inc.

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices:

    Two Carlson Parkway, Suite 260, Minneapolis, Minnesota 55447    

     

    Item 2(a).

    Name of Person Filing:

    Richard Jacinto II

     

    Item 2(b).

    Address of Principal Business Office or, if None, Residence:

    The Reporting Person’s address is 394 Saddle Back Trail, Franklin Lakes, NJ 07417.

     

    Item 2(c).

    Citizenship:

    United States

     

    Item 2(d).

    Title of Class of Securities:

    Voting Common Shares, no par value per share

     

    Item 2(e).

    CUSIP No.:

    25253X207

     

    Item 3.

    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)    ☐    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
    (b)    ☐    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c)    ☐    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d)    ☐    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).
    (e)    ☐    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
    (f)    ☐    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
    (g)    ☐    A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);


    CUSIP No 25253X207    Page 4 of 5

     

    (h)    ☐    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)    ☐    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)    ☐    A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J).
    (k)    ☐    Group, in accordance with §240.13d-1(b)(1)(ii)(K).

     

    Item 4.

    Ownership

     

    (a)

    Amount beneficially owned: 1,649,053 voting common shares (1)

     

    (b)

    Percent of class: 6.2% (2)

     

    (c)

    Number of shares as to which the person has:

     

      (i)

    Sole power to vote or to direct the vote: 1,649,053 voting common shares (1)

     

      (ii)

    Shared power to vote or to direct the vote: 0

     

      (iii)

    Sole power to dispose or to direct the disposition of: 1,649,053 voting common shares (1)

     

      (iv)

    Shared power to dispose or to direct the disposition of: 0

     

    (1)

    Consists of (i) 100,000 voting common shares held by Fidelity Roth IRA Richard Jacinto II – Roth IRA – FMTC Custodian, of which Richard Jacinto II is the beneficiary, and (ii) 1,549,053 voting common shares held by NFS/FMTC Roth IRA FBO Richard Jacinto II, of which Richard Jacinto II is the beneficiary.

     

    (2)

    Based on 26,443,067 voting common shares of the Issuer outstanding as of May 3, 2022.

     

    Item 5.

    Ownership of 5 Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

    Not applicable.


    CUSIP No 25253X207    Page 5 of 5

     

    Item 8.

    Identification and Classification of Members of the Group.

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    Item 10.

    Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: May 27, 2022

     

    By:  

    /s/ Richard Jacinto II

    Name:   Richard Jacinto II
    Get the next $DMAC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DMAC

    DatePrice TargetRatingAnalyst
    11/14/2025Overweight
    Cantor Fitzgerald
    10/30/2025Buy
    TD Cowen
    10/7/2024$7.00Buy
    H.C. Wainwright
    4/24/2024$8.00Buy
    Craig Hallum
    6/22/2023$7.00Perform → Outperform
    Oppenheimer
    6/30/2021$38.00 → $32.00Buy
    Roth Capital
    More analyst ratings

    $DMAC
    SEC Filings

    View All

    DiaMedica Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - DiaMedica Therapeutics Inc. (0001401040) (Filer)

    5/21/26 4:30:35 PM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by DiaMedica Therapeutics Inc.

    10-Q - DiaMedica Therapeutics Inc. (0001401040) (Filer)

    5/6/26 4:38:22 PM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DiaMedica Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - DiaMedica Therapeutics Inc. (0001401040) (Filer)

    5/6/26 4:36:49 PM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DMAC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Stahlberg Jan bought $7,631,469 worth of shares (1,061,277 units at $7.19) (SEC Form 4)

    4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)

    12/8/25 5:15:16 PM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Stahlberg Jan bought $5,958,107 worth of shares (1,000,000 units at $5.96) (SEC Form 4)

    4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)

    9/4/25 2:29:35 PM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Stahlberg Jan bought $5,400,000 worth of shares (1,542,857 units at $3.50) (SEC Form 4)

    4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)

    7/25/25 6:54:18 PM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DMAC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Giuffre Randall Michael

    4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)

    6/3/26 5:28:29 PM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Kuntz Richard

    4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)

    6/3/26 5:27:59 PM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director O'Connor Daniel J.

    4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)

    6/3/26 5:27:26 PM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DMAC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that on July 15, 2026, it granted options to purchase an aggregate of 160,000 shares of DiaMedica’s common stock to a newly hired non-executive employee whose employment commenced in July 2026. The stock options were a material inducement to the employee’s acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of their compensation. The stock options were approved by the Compensation Committee of the Board of Directors and issued

    7/17/26 4:30:00 PM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction

    First clinical evaluation of DM199 (rinvecalinase alfa) in fetal growth restriction, a leading cause of stillbirth with no approved pharmacologic treatment DM199 is intended to improve maternal uterine artery blood flow to the placenta without crossing into fetal circulation Fetal Growth Restriction white paper authored by leading maternal-fetal medicine experts released DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced the dosing of the first two patients in an investigator-sponsored Phase 2 trial evaluating DM199 (rinvecalinase alf

    6/23/26 8:30:00 AM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program

    DiaMedica planning to conduct a rat pharmacokinetic and activity study, which it believes will address FDA-requested data for a preeclampsia IND DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company, today announced that it has received a written response from the U.S. Food and Drug Administration (FDA) regarding the need for additional nonclinical reproductive toxicity data to support continued development of DM199 (rinvecalinase alfa) for the treatment of preeclampsia (PE). DiaMedica believes, based on the FDA's feedback, that the previously completed rat reproductive toxicity study may be acceptable to support a U.S. investigational new drug (IND) appl

    6/16/26 8:30:00 AM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DMAC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald resumed coverage on DiaMedica Therapeutics

    Cantor Fitzgerald resumed coverage of DiaMedica Therapeutics with a rating of Overweight

    11/14/25 12:00:36 PM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TD Cowen initiated coverage on DiaMedica Therapeutics

    TD Cowen initiated coverage of DiaMedica Therapeutics with a rating of Buy

    10/30/25 7:43:04 AM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on DiaMedica Therapeutics with a new price target

    H.C. Wainwright initiated coverage of DiaMedica Therapeutics with a rating of Buy and set a new price target of $7.00

    10/7/24 7:50:42 AM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DMAC
    Leadership Updates

    Live Leadership Updates

    View All

    DiaMedica Therapeutics Appoints Julie Krop, MD, as Chief Medical Officer

    DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced the appointment of Julie Krop, MD, as Chief Medical Officer (CMO), effective immediately. Dr. Krop will succeed Dr. Lorianne Masuoka, who has resigned from her position as CMO for personal reasons. "We are pleased to welcome Dr. Krop to our executive leadership team," said Rick Pauls, President and CEO of DiaMedica. "Her extensive experience in the biopharma industry and track record of advancing innovative therapeutics from proof of concept to approval will be invaluable to our te

    8/6/25 8:00:00 AM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DiaMedica Therapeutics Appoints Daniel J. O'Connor to the Board of Directors

    DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on acute ischemic stroke and preeclampsia, today announced the election of Daniel J. O'Connor to its Board of Directors, effective February 20, 2025. Mr. O'Connor has decades of executive experience and leadership in the biopharmaceutical industry, including as CEO and other executive level leadership positions at Ambrx Biopharma, Inc. (Ambrx), ImClone Systems Incorporated, Bracco Diagnostics, and PharmaNet (today, Syneos Health). Mr. O'Connor has gained a reputation as a seasoned and successful biopharma CEO, most recently serving as President, Chief Executive Officer and Director of Ambrx, wher

    2/24/25 8:30:00 AM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer

    Executive with Strong Track Record in Advancing Pipelines Through Clinical Development DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, announced today the appointment of Lorianne Masuoka, M.D. as Chief Medical Officer. Dr. Masuoka is a board-certified neurologist with more than 25 years of experience and a successful track record of managing clinical programs from early stage to drug approvals and strategic alliances. "We are delighted to have Lorianne join our executive leadership team," said Rick Pauls, DiaMedica's President and Chief Executive Officer. "Sh

    1/22/24 8:23:00 AM ET
    $DMAC
    $MRNS
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DMAC
    Financials

    Live finance-specific insights

    View All

    DiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights

    DM199 Preeclampsia Phase 2 Investigator-Sponsored Trial (IST) Part 1a Expansion Cohort Enrolling, Updated Dataset Expected 2Q 2026 ReMEDy2 Phase 2/3 AIS Trial of DM199 Surpassed 70% of Required Interim Enrollment; Interim Analysis planned in 4Q 2026 $51.3 million in Cash, Cash Equivalents and Investments, Anticipated Runway through 2027 Conference Call and Webcast on May 7 at 8:00 AM ET / 7:00 AM CT DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia (PE), fetal growth restriction (FGR) and acute ischemic stroke (AIS), today provided a business update and reported financial results for the

    5/6/26 4:30:00 PM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026

    DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke (AIS), today announced that its first quarter 2026 financial results will be released after the markets close on Wednesday, May 6th. DiaMedica will host a live conference call on Thursday, May 7th at 8:00 AM Eastern Time / 7:00 AM Central Time to provide a business update and discuss financial results. Conference Call details: Date: Thursday, May 7, 2026 Time: 8:00 AM EDT / 7:00 AM CDT Web access: https://app.webinar.net/nG3yPzRP7wk Dial In: (646)

    4/30/26 8:25:00 AM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights

    Received Regulatory Approval from Health Canada Supporting Initiation of Phase 2 DM199 Study in Early-onset Preeclampsia. DM199 Preeclampsia Phase 2 Investigator-Sponsored Trial (IST) Part 1a Expansion Cohort Enrolling, Completion Expected in 1H 2026. ReMEDy2 Phase 2/3 AIS Trial of DM199 Approaching 70% of Required Interim Enrollment; Interim Analysis planned 2H 2026. $60 million in Cash, Cash Equivalents and Investments, Anticipated Runway through 2H 2027. Conference Call and Webcast on March 31 at 8:00 AM ET / 7:00 AM CT. DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia (PE), fetal

    3/30/26 4:45:00 PM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DMAC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by DiaMedica Therapeutics Inc.

    SC 13G - DiaMedica Therapeutics Inc. (0001401040) (Subject)

    7/8/24 5:23:49 PM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by DiaMedica Therapeutics Inc. (Amendment)

    SC 13G/A - DiaMedica Therapeutics Inc. (0001401040) (Subject)

    6/27/23 4:12:06 PM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by DiaMedica Therapeutics Inc. (Amendment)

    SC 13G/A - DiaMedica Therapeutics Inc. (0001401040) (Subject)

    6/27/23 4:11:32 PM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care